Abstract 2220: Gut microbiome impacts the tumor microenvironment and enhances the effectiveness of anti-PD1 therapy in head and neck cancer
Po‐Han Lin(National Taiwan University Hospital), Ruey‐Long Hong(National Taiwan University), Jessica Ho(Duke-NUS Medical School), Yuan-Chia Chu(National Taiwan University Hospital), Chi‐Maw Lin(National Taiwan University Hospital), Ying‐Cheng Chiang(National Taiwan University Hospital), Chunyu Liu(Jiamusi University), Chong‐Jen Yu(National Taiwan University Hospital), Chenyi Wang(National Taiwan University Hospital), Yahui Chen(Chung Shan Medical University)
Cited by 1
Related Papers
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|1.7k
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6
|The Lancet Oncology|2015|980
Detection and Dynamic Changes of <i>EGFR</i> Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy
|Clinical Cancer Research|2015|469
Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial
|Journal of Clinical Oncology|2023|386
<i>TBX6</i> Null Variants and a Common Hypomorphic Allele in Congenital Scoliosis
|New England Journal of Medicine|2015|317